WO2011110694A2 - Micelle compositions and process for the preparation thereof - Google Patents

Micelle compositions and process for the preparation thereof Download PDF

Info

Publication number
WO2011110694A2
WO2011110694A2 PCT/EP2011/053817 EP2011053817W WO2011110694A2 WO 2011110694 A2 WO2011110694 A2 WO 2011110694A2 EP 2011053817 W EP2011053817 W EP 2011053817W WO 2011110694 A2 WO2011110694 A2 WO 2011110694A2
Authority
WO
WIPO (PCT)
Prior art keywords
micelle composition
hydrophobic
block
composition according
micelle
Prior art date
Application number
PCT/EP2011/053817
Other languages
French (fr)
Other versions
WO2011110694A3 (en
Inventor
Jerome George Jozeph Louis Lebouille
Tessa Kockelkoren
Leopold Franciscus Wijnandus Vleugels
Remco Tuinier
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to US13/634,445 priority Critical patent/US20130102687A1/en
Priority to CA2791559A priority patent/CA2791559A1/en
Priority to JP2012556544A priority patent/JP5842270B2/en
Priority to CN201180013635.XA priority patent/CN102791255B/en
Priority to EP11707688A priority patent/EP2544661A2/en
Publication of WO2011110694A2 publication Critical patent/WO2011110694A2/en
Publication of WO2011110694A3 publication Critical patent/WO2011110694A3/en
Priority to US15/159,736 priority patent/US20160271062A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66—Polyesters containing oxygen in the form of ether groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Definitions

  • the present invention relates to micelle compositions based on amphiphilic block copolymers.
  • the present invention also relates to a process for the preparation of the micelle compositions suitable for medical and/or veterinary use.
  • the invention also relates to articles or devices comprising the micelle composition.
  • the field of the present invention is the area of formulating hydrophobic compounds for use in aqueous systems, in particular, the formulation of relatively insoluble and/or toxic hydrophobic compounds such as cardiovascular drugs, anticancer agents, flavoring agents, vitamins, imaging agents, pigments, flame retardants, agricultural chemicals, fungicides, pesticides or insecticides.
  • relatively insoluble and/or toxic hydrophobic compounds such as cardiovascular drugs, anticancer agents, flavoring agents, vitamins, imaging agents, pigments, flame retardants, agricultural chemicals, fungicides, pesticides or insecticides.
  • amphiphilic block copolymers comprised of hydrophobic and hydrophilic blocks, can assemble into a microphase separated, core/shell architecture in a selective solvent.
  • the hydrophobic compound will be encapsulated into the hydrophobic core of the micelle while the aqueous solubility is provided by the shell of the micelle. Due to their nanoscopic dimensions and properties imparted by the shell, micelles may have long- term circulation capabilities.
  • WO-A-9710849 discloses biodegradable polymeric micelle-type drug compositions and method for the preparation of micelles comprising water insoluble drugs which micelles are composed of amphiphilic di- or tri-block copolymers containing poly(ethylene oxide) as hydrophilic block and ⁇ (- ⁇ - caprolactone) as hydrophobic block.
  • the molecular weight of the amphiphilic block copolymer used to form the micelles is in the range of about 1430 to 6000 Daltons.
  • the resulting micelle- drug composition may be suitable for the sustained release of the water-insoluble drugs in vivo and this effect can be maximized by controlling the molecular weights and the relative ratio of the hydrophilic and hydrophobic blocks.
  • WO-A-9710849 discloses different PLLA-PEO block copolymers and their water solubility's.
  • the water solubility varies from 0.2 g/100 ml to over 20 g/100 ml.
  • a disadvantage of these micelles, which are water soluble, is their tendency to aggregate so that the stability of the micelles on the longer term can not be assured.
  • WO-A-051 18672 discloses micelles for the administration of hydrophobic drugs formed from self-assembly of poly (ethylene oxide)-b-poly ( ⁇ - caprolactone) (PEO-b-PCL) block copolymers with a molecular weight above 6000 Dalton. It was found that the use of higher molecular weight block copolymers in the preparation of the micelles results in less aggregation of micelle particles and a modified biodistribution. This application is however silent about the stability and water solubility of the micelles.
  • PEO-b-PCL poly (ethylene oxide)-b-poly ( ⁇ - caprolactone)
  • compositions for encapsulating poorly (water) soluble compounds for use in pharmaceutical, food, cosmetic and industrial formulations.
  • the encapsulated materials are nanoscopic in size, thermodynamically and kinetically stable, protect the hydrophobic compounds from self-aggregation and provide advantageous release rates.
  • the object of the present invention is to provide a micelle composition comprising amphiphilic block copolymers which result in nanoscopic micelles which are thermodynamically and kinetically stable and which protect the hydrophobic compounds from self-aggregation and provide advantageous release properties.
  • the object of the present invention is achieved by providing a micelle composition comprising an amphiphilic block copolymer containing a hydrophobic block A and a hydrophilic block B composed of monomeric units, whereby the ratio R of the number average molecular weight (M n ) of block A (M n A) divided to the number average molecular weight of block B (M n B) is higher than 0.95 and whereby the amphiphilic block copolymer is characterised by a parameter a whereby
  • M n A number average molecular weight (M n ) of block A
  • M nB number average molecular weight (M n ) of block B
  • micelles can be prepared with an optimum in the amount and the number average molecular weight of the hydrophilic and hydrophobic blocks A and B. It has surprisingly been found that stable micelles can be provided even on the longer term, whereby the tendency of the micelles to aggregate has been reduced markedly. Due to the stability of the micelle
  • the micelles will exhibit enhanced properties on controlled release, shelf- life and exhibiting long circulation times in vivo. Moreover and at the same time the concentration of a drug in the micelle composition can be tailored to meet dosage needs.
  • the micelle compositions of the present invention are capable of controlling the drug release. Such micelle compositions can offer several advantages over
  • conventional dosage forms such as, decreased systemic side effects, and extended effective residence time of the drug, enhanced efficacy (targeted release) and patient's compliance, maintenance of therapeutic levels of the drug for longer time and with narrower fluctuations of drug's concentration in the plasma.
  • the amphiphilic blockcopolymer preferably comprise at least a hydrophobic block A and a hydrophilic block B, the hydrophobic block A comprises at least one hydrophobic polymer X and the hydrophilic block B comprises at least one hydrophilic polymer Y whereby the X and Y units alternate.
  • the hydrophobic polymer X and the hydrophilic polymer Y are composed of monomers.
  • the octanol/water partition coefficient in parameter a is the ratio of the concentrations of a monomer in the two phases of a mixture of two immiscible solvents at equilibrium. Hence these coefficients are a measure of differential solubility of the monomer between these two solvents.
  • Coefficients are "partition constant", “partition ratio” or “distribution ratio”. Normally one of the solvents chosen is water while the second solvent is hydrophobic for example octanol. Hence the partition coefficient is a measure of how "water loving” or “water fearing” a chemical substance is.
  • the octanol-water partition coefficient can be expressed as Log P of a solute which is to be determined using the shake-flask method at a temperature of 25°C and a pressure of 1 bar.
  • X is polycaprolacton
  • the monomer Z is caprolacton and the K 0/w of caprolacton is 3 at 25°C and a pressure of 1 bar.
  • X is polylactic-glycolic acid
  • the monomer Z is lactic acid+glycolic acid and the K 0/w of lactic acid+glycolic acid is 1 .6 at 25°C and a pressure of 1 bar.
  • Further examples of the hydrophobic polymers X are given below.
  • the hydrophobic polymer X and the hydrophilic polymer Y are preferably chosen such that the resulting amphiphilic block copolymer has a solubility in water S w of less than 0.1 g/100 ml, more preferably less than 0.01 g/100ml, most preferably 0.001 g/100ml.
  • the number average molecular weight of the hydrophobic polymer X and hydrophilic polymer Y can be measured via Gel permeation chromatography NMR.
  • End group analysis by NMR offers an easy method for molecular weight (avg. chain length) determination of polymers using an instrument commonly found in many analytical labs and it can also be used to determine the molecular weight of block- copolymer molecules. Sensitivity of the instrument and the subsequent ability to detect end-group protons and the monomer unit protons between the two blocks will determine the upper limit that can be measured. The method relies on a few simple needs such as identifiable end-group and "inter blocks" protons distinguishable from repeating monomer group protons by NMR, accurate integration of these protons and knowledge of monomer formula weights.
  • the M n value can be generated.
  • the outer blocks in the tri-block copolymer this would be the number of the repeating units multiplied by the molecular weight of the repeating unit + the molecular weight of the end-groups.
  • the number of repeating units is determined from the ratio of the integral of the repeating unit protons and the integral of the end-group protons where both are normalized to an integral per proton.
  • For the inner block of the tri-block a similar calculation applies but in this case not the end-group protons but the monomer unit protons between the two blocks are taken. Obviously, also a different molecular weight of the repeating unit applies.
  • Extension to penta-block polymers involves the integration of yet an additional set of monomer unit protons between the extra blocks.
  • amphiphilic blockcopolymers are for example AB di-blocks, ABA- or BAB- tri-blockcopolymers but also multi-block copolymers having repeating BA or AB blocks to make A(BA)n or B(AB)n copolymers where n is an integer of from 2 to 5 are part of the present invention.
  • Both ABA and BAB type triblock copolymers may be synthesized by ring opening polymerization, or condensation polymerization according to reaction schemes disclosed in US-A-5683723 and US-A-5702717, hereby fully incorporated by reference.
  • cyclic ester monomers such as lactide, glycolide, or 1 ,4- dioxan-2-one with monomethoxy poly(ethylene glycol) (mPEG) or poly (ethylene glycol) (PEG) in the presence of stannous octoate as a catalyst at 80-130 Degrees C.
  • the block copolymer product is dissolved in dichloromethane or acetone, precipitated in diethyl ether, hexane, pentane, or heptane, followed by drying.
  • the A blocks are composed of at least a hydrophobic polymer X which may be chosen from the group consisting of polylactides, polycaprolactone, copolymers of lactide and glycolide, copolymers of lactide and caprolactone, copolymers of lactide and 1 ,4-dioxan-2-one, polyorthoesters, polyanhydrides, polyphosphazines, poly(hydroxybutyrate), poly(tetramethylene carbonate) or hydrophobic poly(ester amides), poly(amino acid)s or polycarbonates.
  • Polymer X is utilized because of its biodegradable, biocompatible, and solubilization properties.
  • hydrophobic polymer X is chosen from the group consisting of polylactide, polycaprolactone, a copolymer of lactide and glycolide, a copolymer of lactide and caprolactone, and a copolymer of lactide and 1 ,4-dioxan-2-one.
  • the hydrophobic polymer unit X is for example polylactide the monomer is lactic acid.
  • the A block may of course also comprise more than one hydrophobic polymer X.
  • the number average molecular weight of the hydrophobic polymer X is preferably within the range of 500-20,000 Daltons, and more preferably within the range of 1 ,000-10,000 Daltons.
  • the B blocks comprise at least a hydrophilic polymer Y which may be chosen from hydrophilic polyesteramide, polyvinylalcohol or polyethylene glycol (PEG).
  • PEG is preferably chosen as the hydrophilic, water-soluble block because of its unique biocompatibility, nontoxicity, hydrophilicity, solubilization properties.
  • PEG copolymers based on the L-amino acids can be used.
  • Examples include, without limitation, poly(ethyleneglycol)-b-poly(beta -benzyl-L-glutamate), poly(ethylene glycol)- b-poly(L-lysine acid), polyethylene glycol)-b-poly(aspartic acid, poly(ethylene glycol)- b- poly(beta -benzyl-L-aspartate), and acyl esters of the foregoing block copolymers.
  • the number average molecular weight of the polyalkylene glycol or its derivatives is preferably within the range of 200-20,000 Daltons and more preferably within the range of 1 ,000-15,000 Daltons.
  • the content of the hydrophilic component is within the range of 40-80 wt percent, preferably 40-70 wt percent, based on the total weight of the block copolymer.
  • amphiphilic block copolymer it is a triblock copolymer composed of X-Y-X.
  • the triblock copolymer preferably comprises as polymer X polylactic acid, a hydrophobic polyesteramide or polycaprolactone and as polymerY preferably polyethyleneglycol, polyvinylalcohol or a hydrophilic
  • polyesteramide examples include, but are not limited to PLGA-PEG-PLGA, PCL-PEG-PCL or poly (L-amino acid)-PEG-poly (L-amino acid) polymers.
  • monomodal micelles compositions This is however dependent on the water solubility S w of the amphiphilic blockcopolymer. It has been found that monomodal micelle compositions can be prepared if the amphiphilic block copolymer has a very low water solubility S w preferably an S w of less than 0.1 g/100 ml, more preferably an S w of less than 0.01 g/100ml, most preferably an S w of less than 0.001 g/100ml.
  • non-modal micelle composition refers to an unfiltered micelle composition
  • the invention relates to monomodal micelle compositions comprising a hydrophobic compound and an amphiphilic block copolymer, wherein the amphiphilic block copolymer consists of a hydrophobic blocks A and hydrophilic blocks B whereby the block A consists of one and the same hydrophobic polymer X and hydrophilic block B consists of one hydrophilic polymer Y, whereby the X and Y blocks alternate as X-Y-X.
  • the ratio R of the number average molecular weight (M n ) of block A (M n A ) divided to the number average molecular weight of block B (M n B ) is higher than 0.95.
  • the R is higher than 1 .3 more preferably higher than 1.7, even more preferably higher than 2, most preferably higher than 3, for example higher than 3.5.
  • the number average molecular weight of the amphiphilic block copolymer is chosen, at least in part, according to the size and flexibility of the hydrophobic compound.
  • the hydrophobic compound as used herein is a compound which is not freely soluble in water and which is encapsulated within the amphiphilic block copolymer according to the present invention. Examples of the hydrophobic
  • hydrophobic drugs such as anticancer agents, antiinflammatory agents, antifungal agents, antiemetics, antihypertensive agents, sex hormones, and steroids.
  • hydrophobic drugs are: anticancer agents such as paclitaxel, camptothecin, doxorubicin, daunomycin, cisplatin, 5-fluorouracil, mitomycin, methotrexate, and etoposide; antiinflammatory agents such as indomethacin, ibuprofen, ketoprofen, flubiprofen, diclofenac, piroxicam, tenoxicam, naproxen, aspirin, and acetaminophen; antifungal agents such as itraconazole, ketoconazole, and amphotericin; sex hormons such as testosterone, estrogen, progestone, and estradiol; steroids such as dexamethasone, prednisolone, and triamcinolone; antihypertensive
  • hydrophobic compounds are food ingredients, vitamins, pigments, dyes, insect repellents, UV light absorbing compounds, catalysts, photo-/UV-stabilizers, fungicides, insecticides or flame retardants.
  • the hydrophobic compound may be selected from the group of nutrients, drugs,
  • the hydrophobic compound may be capable of stimulating or suppressing a biological response.
  • the hydrophobic compound may for example be chosen from growth factors (VEGF, FGF, MCP-1 , PIGF, anti-inflammatory compounds, antithrombogenic compounds, anti-claudication drugs, anti-arrhythmic drugs, anti- atherosclerotic drugs, antihistamines, cancer drugs, vascular drugs, ophthalmic drugs, amino acids, vitamins, hormones, neurotransmitters, neurohormones, enzymes, signalling molecules and psychoactive medicaments.
  • growth factors VEGF, FGF, MCP-1 , PIGF, anti-inflammatory compounds, antithrombogenic compounds, anti-claudication drugs, anti-arrhythmic drugs, anti- atherosclerotic drugs, antihistamines, cancer drugs, vascular drugs, ophthalmic drugs, amino acids, vitamins, hormones, neurotransmitters, neurohormones, enzymes, signalling molecules and psychoactive medicaments.
  • hydrophobic drugs are neurological drugs
  • alphal adrenoceptor antagonist prazosin, terazosin, doxazosin, ketenserin, urapidil
  • alpha2 blockers arginine, nitroglycerin
  • hypotensive clonidine, methyldopa, moxonidine, hydralazine minoxidil
  • bradykinin angiotensin receptor blockers
  • angiotensin receptor blockers (benazepril, captopril, cilazepril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril, zofenopril), angiotensin-1 blockers
  • beta2 agonists acebutolol, atenolol, bisoprolol, celiprolol, esmodol, metoprolol, nebivolol, betaxolol
  • beta2 blockers carvedilol, labetalol, oxprenolol, pindolol, propanolol
  • diuretic actives chlortalidon, chlorothiazide, epitizide
  • the hydrophobic drugs can be delivered for local delivery or as pre or post surgical therapies for the management of pain, osteomyelitis, osteosarcoma, joint infection, macular degeneration, diabetic eye, diabetes mellitus, psoriasis, ulcers, atherosclerosis, claudication, thrombosis viral infection, cancer or in the treatment of hernia.
  • micelle(s) refers only to the amphiphilic block copolymers assembled into a microphase separated, core/shell architecture in a selective organic solvent.
  • a micelle (plural micelles, micella, or micellae) is an aggregate of amphiphilic molecules dispersed in a liquid.
  • a typical micelle in aqueous solution forms an aggregate with the hydrophilic "head” regions in contact with surrounding solvent, sequestering the hydrophobic regions in the micelle centre.
  • Micelles are approximately spherical in shape. Other phases, including shapes such as ellipsoids, cylinders, and rods are also possible.
  • the shape and size of a micelle is a function of the molecular geometry of its molecules and solution conditions such as concentration, temperature, pH, and ionic strength.
  • the micelle composition according to the present invention may comprise a further hydrophobic core excipient such as a fatty acid, a vitamine or any hydrophobic polymer such as for example polycaprolactone.
  • a further hydrophobic core excipient such as a fatty acid, a vitamine or any hydrophobic polymer such as for example polycaprolactone.
  • the release properties can be further steered.
  • the size of the micelles can be adjusted in this way.
  • the micelle composition of the present invention may optionally comprise a lyoprotectant.
  • a lyoprotectant acts as a stabilizer for the loaded micelles during for example freeze drying. In this way the micelles do not coalesce so that the dried product does not readily disperse when an aqueous dispersant is added.
  • the lyoprotectant can be a saccharide or polyol, for example, trehalose, sucrose or raffinose, or another hydrophilic polyol such as maltodextrin, fructose, glycerol, sorbitol, inositol and mannose. Lyoprotectants can also be materials other than sugars such as PEG.
  • the ratio of amphiphilic block copolymer to hydrophobic core excipient or lyoprotectant ranges from 1 :1 w/w to about 1 :50 w/w, preferably from 1 :1 w/w to 1 :10 w/w, advantageously to 1 :5 w/w.
  • the lyoprotectant can be added to the solvent along with the hydrophobic compound and the amphiphilic block copolymer or it can be added to water upon bringing into water, the solution of the hydrophobic compound and the amphiphilic block copolymer formed in the organic solvent.
  • the micelle composition according to the present invention may be a mixture of amphiphilic blockcopolymers.
  • the micelle composition may further comprise an amphiphilic di block copolymer containing a hydrophobic block A and a hydrophilic block B wherein the hydrophobic block A comprises at least one hydrophobic polymer X and the hydrophilic block B comprises at least one hydrophilic polymer Y.
  • the amount of diblock copolymer may vary up to 30 wt% of the total composition.
  • the micelles according to the present invention comprise an average particle size in the range of 10-800 nm, preferably 15-600 nm, more preferably 20-400 nm, most preferably in the range of 25-200 nm.
  • the desired size is strongly dependent on the application and can be adjusted accordingly.
  • the size of the micelles was determined by Dynamic Light Scattering (DLS) (Zetasizer Nano ZS, Malvern
  • micelles can be fabricated using a variety of techniques such as spray drying, freeze spray evaporation or emulsification (co-solvent evaporation). It is known to the person skilled in the art that the physical and chemical properties of micelles fabricated via emulsification, are greatly depended on the emulsification processing steps one applies for preparing the micelles.
  • WO-A-03082303 discloses a process for the preparation of micelles which micelles comprise an amphiphilic block copolymers and a hydrophobic compound, and optionally a lyoprotectant or micelles' stabilizer.
  • the process steps for producing the micelles include dissolving the hydrophobic compound and the amphiphilic block copolymer in a volatile organic solvent and then adding water to the miscible solution, with mixing, to promote the formation of micelles and the partitioning of the
  • the hydrophobic compound into the micelle cores The water is added slowly to induce micellization through the critical water content of the amphiphilic block copolymers (level of water required for assembly of the amphiphilic block copolymers). The water content is greater than the critical weight concentration (CWC). Subsequently, the organic solvent is removed by evaporation under reduced pressure or elevated temperature. After loading, the micelles based on the amphiphilic block copolymers can be freeze dried for later reconstitution.
  • CWC critical weight concentration
  • CWC critical weight concentration
  • the present invention further relates to a process for preparing the micelle composition wherein the process comprises the steps of:
  • the hydrophobic compound is a therapeutic agent.
  • the micelle composition may also comprise more than one hydrophobic compound.
  • the concentration of the amphiphilic block copolymer in the organic solvent depends on the organic solvent used. For example in case that acetone is used as a solvent the concentration of the amphiphilic block copolymer at most 130 mg/mL (milligram per litre), preferably is at most 100 mg/L, more preferably is at most 65 mg/L.
  • an organic solvent is a water miscible liquid used to produce a solution with at least one amphiphilic block copolymer and at least one hydrophobic compound.
  • the solvent is one which desirably has a boiling temperature lower than that of water (less than 100 degrees centigrade at 1 atm).
  • the organic solvent forms an azeotrope with water, advantageously a negative azeotrope.
  • the azeoptropic mixture can be dried by removing the azeotrope under conditions of decreased pressure and/or elevated temperature.
  • Examples include without limitation, acetone, methanol, ethanol, acetonitrile, tetrahydrofurane, propanol, isopropanol, ethyl acetate, etc.
  • the organic solvent is selected from the group consisting of acetone, tetrahydrofurane, methanol, ethanol, acetonitirile or mixtures thereof.
  • the aqueous medium is selected from the group consisting of water, saline solution or a buffer solution with a pH in the range of 1-14.
  • the process of the present invention offers enhanced control over the micelles' average particle size and distribution, the possibility to skip laborious and/or expensive process steps such as solvent evaporation, drying, sterilization, etc., Moreover the process is insensitive to the amount and/or the addition rate of water, it does not comprise a micelle's stabilizer such as a surfactant, it can be executed continuous on either small or large scale thus providing a robust, scalable and economically attractive method for the preparation of the micelle compositions.
  • the process of the present invention can also provide micelle compositions that can also exhibit one or more enhanced properties such as enhanced controlled release, enhanced self-life, being directly injectable and at the same time the concentration of the drug in the micelle composition can be tailored to meet dosage needs.
  • the process can be reversed to encapsulate hydrophilic compounds.
  • a functional group in particular with a signalling molecule, an enzyme or a receptor molecule, such as an antibody.
  • the receptor molecule may for instance be a receptor molecule for a component of interest, which is to be purified or detected, e.g. as part of a diagnostic test, making use of the particles of the present invention.
  • Suitable functionalisation methods may be based on a method known in the art.
  • boundary value is included in each range for each parameter. All combinations of minimum and maximum values of the parameters described herein may be used to define the parameter ranges for various embodiments and preferences of the invention.
  • the total sum of any quantities expressed herein as percentages cannot (allowing for rounding errors) exceed 100 %.
  • the sum of all components of which the composition of the invention (or part(s) thereof) comprises may, when expressed as a weight (or other) percentage of the composition (or the same part(s) thereof), total 100 % allowing for rounding errors.
  • the sum of the percentage for each of such components may be less than 100 % to allow a certain percentage for additional amount(s) of any additional compound(s) that may not be explicitly described herein.
  • the micelle composition of the present invention can be any organic compound having the micelle composition of the present invention.
  • Parenteral administration includes intravenous, infraperitoneal,
  • the micelles of the invention can be any suitable material that can be used for parenteral administration.
  • Parenteral administration may be by continuous infusion over a selected period of time.
  • the micelles of the invention can be any suitable material that can be used for parenteral administration.
  • the micelles of the present invention may be incorporated within an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • the micelle composition of the invention may also be administered parenterally. Solutions of the micelle
  • composition according to the present invention can be prepared in water. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. A person skilled in the art would know how to prepare suitable formulations.
  • the fields wherein the micelles according to the present invention can be used include dermatology, vascular, orthopedics, ophthalmic, spinal, intestinal, pulmonary, nasal, or auricular.
  • the micelles according to the present invention may inter alia be used in an agricultural or food application.
  • such micelles may comprise food additives, pesticides, insecticides or plant-nutrients.
  • the present invention further relates to articles comprising the micelle composition of the present invention.
  • the invention provides for a device comprising the micelle composition of the present invention.
  • an article is an individual object or item or element of a class designed to serve a purpose or perform a special function and can stand alone.
  • the invention provides for a device comprising the article of the present invention.
  • a device is a piece of equipment or a mechanism designed to serve a special purpose or perform a special function and can consist of more than one article (multi-article assembly).
  • Examples of devices include, but are not limited to catheters, stents, rods, implants.
  • the invention provides for the use of the micelle composition of the invention, the article of the invention, the device of the invention in medical applications such as therapeutic cardiovascular applications, veterinary applications, food processing applications, flame retardant applications, coatings, adhesives and cosmetics, fabric/textiles, industrial and art applications.
  • the invention provides for a micelle composition of the present invention for use as a medicament.
  • the invention provides for the use of a micelle composition of the present invention for the manufacture of a medicament for cardiovascular therapeutic applications.
  • the invention provides for a method for manufacturing a medicament intended for cardiovascular therapeutic applications characterized in that the micelle composition of the present invention is used.
  • -Rapamycin and paclitaxol were purchased from Oscar Tropitz.
  • Pdl Polydispersity
  • -Mn can be measured as followed.
  • An example is given for PLGA.
  • the concentration of glycolic acid and lactic acid was determined on an Agilent 1 100 LC-MS system, which consists of a binary pump, degasser, autosampler, column oven, diode-array detector and a time-of-flight-MS.
  • the ESI-MS was run in negative mode, with the following conditions: m/z 50-3200, 215 V fragmentor, 0.94 cycl/sec, 350°C drying gas temperature, 12 L N2/min drying gas, 45 psig nebuliser pressure and 4 kV capillary voltage. UV detection was performed at 195 nm.
  • the separation was performed with a 250x4.6 mm Prevail-C18 column (Alltech, USA) at room temperature and with a gradient of 50 mM sulfonic acid in ultra-pure water (mobile phase A) and acetonitrile (mobile phase B).
  • the flow rate was 0.5 mL/min and injection volume was 5 ⁇ .
  • the weight-average molecular weight (Mn) and concentration of PEG was determined by SEC using a highly polar hydroxylated methacrylate 8x300 mm Suprema 1000 A column (10 ⁇ particle size), with a separation range of 1 -100 kDa (PSS, Mainz, Germany).
  • the mobile phase 0.1 M NH4Ac was pumped at a flow rate of 1 .0 mL/min.
  • the SEC analysis was performed using an Agilent 1 100 LC-DAD
  • Example 1 Preparation of PLGA-PEG-PLGA triblock copolymers via ring opening polymerization.
  • PEG was weighed into a two-necked round bottle flask after drying for 24 hours in a vacuum oven at 90°C and subsequently placed in an oil bath at 150°C. A vacuum was employed for at least 60 minutes before continuing synthesis.
  • the reaction conditions were maintained for 20 hours where after the vacuum was replaced by nitrogen gas.
  • the copolymers obtained in this wa are listed below.
  • amphiphilic block copolymer is a PLGA-PEG-
  • the ratio R of the number average molecular weight (M n ) of block A (M n A) divided to the number average molecular weight of block B (M n B) is 2.5 and the amphiphilic block copolymer is characterised by parameter a being 5.24 and calculated as followed :
  • the triblock copolymers of examples 1 and 2 were dissolved in acetone at a weight percentage of 10-20% and filtered over an Acrodisc premium 25 mm Syringe filter, ⁇ /0.45 ⁇ PVDF membrane, to remove particulate impurities and dust particles, which can interfere with the nanoprecipitation process.
  • the filtered solution was collected into a beaker of 500 ml. PTFE and evaporated to remove the solvent over night (10-12 hours) at maximum 40°C and minimum 300mbar.
  • Example 4 Preparation of a drug loaded micelle composition based on PLGA-PEG- PLGA
  • the formulation was filtered over a 0.45 ⁇ filter to remove dust particles. 1 ml of the filtered formulation was pipetted into 25 ml of MilliQ water and measured by Dynamic light scattering (DLS).
  • DLS Dynamic light scattering
  • Example 5 Preparation of a drug loaded micelle composition based on PCL-PEG-PCL
  • Rapamycin and PCL 80k was dissolved in the (PCL 2k) 2 -PEG 3k / Acetone solution. The formulation was filtered over a 0.45 ⁇ filter. 1 ml of the filtered formulation was pipetted into 25 ml of MilliQ water and measured by DLS.
  • Example 6 Preparation of micelle compositions based on PLGA-PEG-PLGA
  • Example 7 Size stability of micelle compositions in time.
  • Rapamycin was dissolved in 0.800ml acetone solution. The formulation was filtered over a 0.45 ⁇ filter to remove dust particles.
  • Example 8 Size stability of micelle compositions in time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a micelle composition comprising a hydrophobic compound and an amphiphilic block copolymer, wherein the amphiphilic block copolymer consists of a hydrophobic block A and a hydrophilic block B, the hydrophobic block A comprises at least one hydrophobic polymeric unit X and the hydrophilic block B comprises at least one hydrophilic polymeric unit Y whereby the X and Y blocks alternate. The present invention further relates to a process for the preparation of the micelle composition wherein the process comprises the steps of: a) dissolving the hydrophobic compound and the amphiphilic block copolymer in an organic solvent to form a solution, b) adding said organic solution into an aqueous medium, c) optionally repeating aforementioned steps. The micelle composition according to the present invention is useful in medical applications such as therapeutic cardiovascular applications, veterinary applications, food processing applications, flame retardant applications, coatings, adhesives and cosmetics, fabric/textiles, industrial and art applications.

Description

MICELLE COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF
The present invention relates to micelle compositions based on amphiphilic block copolymers. The present invention also relates to a process for the preparation of the micelle compositions suitable for medical and/or veterinary use. The invention also relates to articles or devices comprising the micelle composition.
The field of the present invention is the area of formulating hydrophobic compounds for use in aqueous systems, in particular, the formulation of relatively insoluble and/or toxic hydrophobic compounds such as cardiovascular drugs, anticancer agents, flavoring agents, vitamins, imaging agents, pigments, flame retardants, agricultural chemicals, fungicides, pesticides or insecticides.
Currently, potentially hydrophobic compounds have properties that can result in their classification as "challenging" (poorly-water-soluble) compounds. Such molecules have favorable in vitro capabilities, however due to characteristics such as poor aqueous solubility, toxicity, chemical instability, and limited cellular permeability, these compounds require formulation to be effective (Davis, S.S. et al. (1998) Int. J. Pharm. 179, 2).
Micelle systems based on amphiphilic block copolymers have been used to formulate such challenging compounds (Jones, M.C et al. (1999) Eur. J.
Pharm. Biopharm. 48, 101 ). The amphiphilic block copolymers comprised of hydrophobic and hydrophilic blocks, can assemble into a microphase separated, core/shell architecture in a selective solvent. In an aqueous environment, the hydrophobic compound will be encapsulated into the hydrophobic core of the micelle while the aqueous solubility is provided by the shell of the micelle. Due to their nanoscopic dimensions and properties imparted by the shell, micelles may have long- term circulation capabilities.
WO-A-9710849 discloses biodegradable polymeric micelle-type drug compositions and method for the preparation of micelles comprising water insoluble drugs which micelles are composed of amphiphilic di- or tri-block copolymers containing poly(ethylene oxide) as hydrophilic block and ρο^(-ξ- caprolactone) as hydrophobic block. The molecular weight of the amphiphilic block copolymer used to form the micelles is in the range of about 1430 to 6000 Daltons. The resulting micelle- drug composition may be suitable for the sustained release of the water-insoluble drugs in vivo and this effect can be maximized by controlling the molecular weights and the relative ratio of the hydrophilic and hydrophobic blocks. WO-A-9710849 discloses different PLLA-PEO block copolymers and their water solubility's. The water solubility varies from 0.2 g/100 ml to over 20 g/100 ml. A disadvantage of these micelles, which are water soluble, is their tendency to aggregate so that the stability of the micelles on the longer term can not be assured.
WO-A-051 18672 discloses micelles for the administration of hydrophobic drugs formed from self-assembly of poly (ethylene oxide)-b-poly (ξ- caprolactone) (PEO-b-PCL) block copolymers with a molecular weight above 6000 Dalton. It was found that the use of higher molecular weight block copolymers in the preparation of the micelles results in less aggregation of micelle particles and a modified biodistribution. This application is however silent about the stability and water solubility of the micelles.
There is a long felt need in the art for compositions for encapsulating poorly (water) soluble compounds for use in pharmaceutical, food, cosmetic and industrial formulations. Desirably the encapsulated materials are nanoscopic in size, thermodynamically and kinetically stable, protect the hydrophobic compounds from self-aggregation and provide advantageous release rates.
Therefore the object of the present invention is to provide a micelle composition comprising amphiphilic block copolymers which result in nanoscopic micelles which are thermodynamically and kinetically stable and which protect the hydrophobic compounds from self-aggregation and provide advantageous release properties.
The object of the present invention is achieved by providing a micelle composition comprising an amphiphilic block copolymer containing a hydrophobic block A and a hydrophilic block B composed of monomeric units, whereby the ratio R of the number average molecular weight (Mn) of block A (Mn A) divided to the number average molecular weight of block B (Mn B) is higher than 0.95 and whereby the amphiphilic block copolymer is characterised by a parameter a whereby
3 < a < 5.5;
a = Mn A/ (MnA+ MnB) x K0/w A x VMtot in which
Mn A = number average molecular weight (Mn) of block A
MnB = number average molecular weight (Mn) of block B
Ko/wA = Octanol/water partition coefficient of the monomeric units of hydrophobic block A
Mtot = MnA + MnB Unexpectedly it has been found that micelles can be prepared with an optimum in the amount and the number average molecular weight of the hydrophilic and hydrophobic blocks A and B. It has surprisingly been found that stable micelles can be provided even on the longer term, whereby the tendency of the micelles to aggregate has been reduced markedly. Due to the stability of the micelle
compositions, the micelles will exhibit enhanced properties on controlled release, shelf- life and exhibiting long circulation times in vivo. Moreover and at the same time the concentration of a drug in the micelle composition can be tailored to meet dosage needs. The micelle compositions of the present invention are capable of controlling the drug release. Such micelle compositions can offer several advantages over
conventional dosage forms such as, decreased systemic side effects, and extended effective residence time of the drug, enhanced efficacy (targeted release) and patient's compliance, maintenance of therapeutic levels of the drug for longer time and with narrower fluctuations of drug's concentration in the plasma.
The amphiphilic blockcopolymer preferably comprise at least a hydrophobic block A and a hydrophilic block B, the hydrophobic block A comprises at least one hydrophobic polymer X and the hydrophilic block B comprises at least one hydrophilic polymer Y whereby the X and Y units alternate. The hydrophobic polymer X and the hydrophilic polymer Y are composed of monomers.
If a <3, the amphiphilic blockcopolymers become water soluble, which leads to aggregation and instable micelles. If a >5.5 the micelles become unstable. The octanol/water partition coefficient in parameter a is the ratio of the concentrations of a monomer in the two phases of a mixture of two immiscible solvents at equilibrium. Hence these coefficients are a measure of differential solubility of the monomer between these two solvents. Appropriate alternatives for the phrase "Partition
Coefficient" are "partition constant", "partition ratio" or "distribution ratio". Normally one of the solvents chosen is water while the second solvent is hydrophobic for example octanol. Hence the partition coefficient is a measure of how "water loving" or "water fearing" a chemical substance is. The octanol-water partition coefficient can be expressed as Log P of a solute which is to be determined using the shake-flask method at a temperature of 25°C and a pressure of 1 bar. It consists of dissolving some of the solute, in the present invention the monomer Z of which hydrophobic polymer X is composed, in a volume of octanol and water, shaking the mixture and then measuring the concentration of the monomer Z in each solvent. The concentration of the monomer Z can be measured using UV/VIS spectroscopy. Log P =log [Z]octanoi / [Z] water This means that [Z] in the present invention is the concentration of the monomer, from which hydrophobic polymer X is composed, in octanol or water. If X is polylactide the monomer Z is lactic acid and the K0/w of lactic acid is 1 at 25°C and a pressure of 1 bar. If X is polycaprolacton the monomer Z is caprolacton and the K0/w of caprolacton is 3 at 25°C and a pressure of 1 bar. If X is polylactic-glycolic acid the monomer Z is lactic acid+glycolic acid and the K0/w of lactic acid+glycolic acid is 1 .6 at 25°C and a pressure of 1 bar. Further examples of the hydrophobic polymers X are given below.
The hydrophobic polymer X and the hydrophilic polymer Y are preferably chosen such that the resulting amphiphilic block copolymer has a solubility in water Sw of less than 0.1 g/100 ml, more preferably less than 0.01 g/100ml, most preferably 0.001 g/100ml. The lower the solubility of the amphiphilic block copolymer in water, the more stable micelles can be prepared. Even most preferred the amphiphilic block copolymer is water insoluble. Water solubility of amphiphilic blockcopolymers can be measured as for example disclosed in WO9710849, which is incorporated by reference.
The number average molecular weight of the hydrophobic polymer X and hydrophilic polymer Y can be measured via Gel permeation chromatography NMR. End group analysis by NMR offers an easy method for molecular weight (avg. chain length) determination of polymers using an instrument commonly found in many analytical labs and it can also be used to determine the molecular weight of block- copolymer molecules. Sensitivity of the instrument and the subsequent ability to detect end-group protons and the monomer unit protons between the two blocks will determine the upper limit that can be measured. The method relies on a few simple needs such as identifiable end-group and "inter blocks" protons distinguishable from repeating monomer group protons by NMR, accurate integration of these protons and knowledge of monomer formula weights. Once the ratio of protons on the end-groups to protons on the polymer chain is determined, the Mn value can be generated. For the outer blocks in the tri-block copolymer this would be the number of the repeating units multiplied by the molecular weight of the repeating unit + the molecular weight of the end-groups. The number of repeating units is determined from the ratio of the integral of the repeating unit protons and the integral of the end-group protons where both are normalized to an integral per proton. For the inner block of the tri-block a similar calculation applies but in this case not the end-group protons but the monomer unit protons between the two blocks are taken. Obviously, also a different molecular weight of the repeating unit applies. Extension to penta-block polymers involves the integration of yet an additional set of monomer unit protons between the extra blocks.
The amphiphilic blockcopolymers are for example AB di-blocks, ABA- or BAB- tri-blockcopolymers but also multi-block copolymers having repeating BA or AB blocks to make A(BA)n or B(AB)n copolymers where n is an integer of from 2 to 5 are part of the present invention. Both ABA and BAB type triblock copolymers may be synthesized by ring opening polymerization, or condensation polymerization according to reaction schemes disclosed in US-A-5683723 and US-A-5702717, hereby fully incorporated by reference. For example they may be prepared via ring opening polymerization of one of the cyclic ester monomers, such as lactide, glycolide, or 1 ,4- dioxan-2-one with monomethoxy poly(ethylene glycol) (mPEG) or poly (ethylene glycol) (PEG) in the presence of stannous octoate as a catalyst at 80-130 Degrees C. The block copolymer product is dissolved in dichloromethane or acetone, precipitated in diethyl ether, hexane, pentane, or heptane, followed by drying.
The A blocks are composed of at least a hydrophobic polymer X which may be chosen from the group consisting of polylactides, polycaprolactone, copolymers of lactide and glycolide, copolymers of lactide and caprolactone, copolymers of lactide and 1 ,4-dioxan-2-one, polyorthoesters, polyanhydrides, polyphosphazines, poly(hydroxybutyrate), poly(tetramethylene carbonate) or hydrophobic poly(ester amides), poly(amino acid)s or polycarbonates. Polymer X is utilized because of its biodegradable, biocompatible, and solubilization properties. The in vitro and in vivo degradation of the hydrophobic, biodegradable polymer X is well understood and the degradation products are naturally occurring compounds that are readily metabolized and/or eliminated by the patient's body. Preferably, hydrophobic polymer X is chosen from the group consisting of polylactide, polycaprolactone, a copolymer of lactide and glycolide, a copolymer of lactide and caprolactone, and a copolymer of lactide and 1 ,4-dioxan-2-one. As evident in case that the hydrophobic polymer unit X is for example polylactide the monomer is lactic acid. The A block may of course also comprise more than one hydrophobic polymer X.
The number average molecular weight of the hydrophobic polymer X is preferably within the range of 500-20,000 Daltons, and more preferably within the range of 1 ,000-10,000 Daltons.
The B blocks comprise at least a hydrophilic polymer Y which may be chosen from hydrophilic polyesteramide, polyvinylalcohol or polyethylene glycol (PEG). PEG is preferably chosen as the hydrophilic, water-soluble block because of its unique biocompatibility, nontoxicity, hydrophilicity, solubilization properties. Also PEG copolymers based on the L-amino acids can be used. Examples include, without limitation, poly(ethyleneglycol)-b-poly(beta -benzyl-L-glutamate), poly(ethylene glycol)- b-poly(L-lysine acid), polyethylene glycol)-b-poly(aspartic acid, poly(ethylene glycol)- b- poly(beta -benzyl-L-aspartate), and acyl esters of the foregoing block copolymers. The number average molecular weight of the polyalkylene glycol or its derivatives is preferably within the range of 200-20,000 Daltons and more preferably within the range of 1 ,000-15,000 Daltons. The content of the hydrophilic component is within the range of 40-80 wt percent, preferably 40-70 wt percent, based on the total weight of the block copolymer.
Most preferably the amphiphilic block copolymer it is a triblock copolymer composed of X-Y-X. The triblock copolymer preferably comprises as polymer X polylactic acid, a hydrophobic polyesteramide or polycaprolactone and as polymerY preferably polyethyleneglycol, polyvinylalcohol or a hydrophilic
polyesteramide. Specific examples include, but are not limited to PLGA-PEG-PLGA, PCL-PEG-PCL or poly (L-amino acid)-PEG-poly (L-amino acid) polymers.
It was moreover found that it is possible to produce monomodal micelles compositions. This is however dependent on the water solubility Sw of the amphiphilic blockcopolymer. It has been found that monomodal micelle compositions can be prepared if the amphiphilic block copolymer has a very low water solubility Sw preferably an Sw of less than 0.1 g/100 ml, more preferably an Sw of less than 0.01 g/100ml, most preferably an Sw of less than 0.001 g/100ml.
In the context of the present invention the term of "monomodal micelle composition" refers to an unfiltered micelle composition.
In a preferred embodiment, the invention relates to monomodal micelle compositions comprising a hydrophobic compound and an amphiphilic block copolymer, wherein the amphiphilic block copolymer consists of a hydrophobic blocks A and hydrophilic blocks B whereby the block A consists of one and the same hydrophobic polymer X and hydrophilic block B consists of one hydrophilic polymer Y, whereby the X and Y blocks alternate as X-Y-X. The ratio R of the number average molecular weight (Mn) of block A (Mn A) divided to the number average molecular weight of block B (Mn B), is higher than 0.95. Preferably the R is higher than 1 .3 more preferably higher than 1.7, even more preferably higher than 2, most preferably higher than 3, for example higher than 3.5. The number average molecular weight of the amphiphilic block copolymer is chosen, at least in part, according to the size and flexibility of the hydrophobic compound.
The hydrophobic compound as used herein is a compound which is not freely soluble in water and which is encapsulated within the amphiphilic block copolymer according to the present invention. Examples of the hydrophobic
compounds include hydrophobic drugs such as anticancer agents, antiinflammatory agents, antifungal agents, antiemetics, antihypertensive agents, sex hormones, and steroids. Typical examples of the hydrophobic drugs are: anticancer agents such as paclitaxel, camptothecin, doxorubicin, daunomycin, cisplatin, 5-fluorouracil, mitomycin, methotrexate, and etoposide; antiinflammatory agents such as indomethacin, ibuprofen, ketoprofen, flubiprofen, diclofenac, piroxicam, tenoxicam, naproxen, aspirin, and acetaminophen; antifungal agents such as itraconazole, ketoconazole, and amphotericin; sex hormons such as testosterone, estrogen, progestone, and estradiol; steroids such as dexamethasone, prednisolone, and triamcinolone; antihypertensive agents such as captopril, ramipril, terazosin, minoxidil, and parazosin; antiemetics such as ondansetron and granisetron; antibiotics such as penicillin's for example B-lactams, chloramphenicol, metronidazole and fusidic acid; cyclosporine and biphenyl dimethyl dicarboxylic acid. Other examples of hydrophobic compounds are food ingredients, vitamins, pigments, dyes, insect repellents, UV light absorbing compounds, catalysts, photo-/UV-stabilizers, fungicides, insecticides or flame retardants. In particular, the hydrophobic compound may be selected from the group of nutrients, drugs,
pharmaceuticals, proteins and peptides, vaccines, genetic materials, (such as polynucleotides, oligonucleotides, plasmids, DNA and RNA), diagnostic agents, and imaging agents.
The hydrophobic compound may be capable of stimulating or suppressing a biological response. The hydrophobic compound may for example be chosen from growth factors (VEGF, FGF, MCP-1 , PIGF, anti-inflammatory compounds, antithrombogenic compounds, anti-claudication drugs, anti-arrhythmic drugs, anti- atherosclerotic drugs, antihistamines, cancer drugs, vascular drugs, ophthalmic drugs, amino acids, vitamins, hormones, neurotransmitters, neurohormones, enzymes, signalling molecules and psychoactive medicaments.
More examples of hydrophobic drugs are neurological drugs
(amphetamine, methylphenidate), alphal adrenoceptor antagonist (prazosin, terazosin, doxazosin, ketenserin, urapidil), alpha2 blockers (arginine, nitroglycerin), hypotensive (clonidine, methyldopa, moxonidine, hydralazine minoxidil), bradykinin, angiotensin receptor blockers (benazepril, captopril, cilazepril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril, zofenopril), angiotensin-1 blockers
(candesartan, eprosartan, irbesartan, losartan, telmisartan, valsartan), endopeptidase (omapatrilate), beta2 agonists (acebutolol, atenolol, bisoprolol, celiprolol, esmodol, metoprolol, nebivolol, betaxolol), beta2 blockers (carvedilol, labetalol, oxprenolol, pindolol, propanolol) diuretic actives (chlortalidon, chlorothiazide, epitizide,
hydrochlorthiazide, indapamide, amiloride, triamterene), calcium channel blockers (amlodipin, barnidipin, diltiazem, felodipin, isradipin, lacidipin, lercanidipin, nicardipin, nifedipin, nimodipin, nitrendipin, verapamil), anti arthymic active (amiodarone, solatol, diclofenac, enalapril, flecainide) or ciprofloxacin, latanoprost, flucloxacillin, rapamycin and analogues and limus derivatives, paclitaxel, taxol, cyclosporine, heparin, corticosteroids (triamcinolone acetonide, dexamethasone, fluocinolone acetonide), anti- angiogenic (iRNA, VEGF antagonists: bevacizumab, ranibizumab, pegaptanib), growth factor, zinc finger transcription factor, triclosan, insulin, salbutamol, oestrogen, norcantharidin, microlidil analogues, prostaglandins, statins, chondroitinase, diketopiperazines, macrocycli compounds, neuregulins, osteopontin, alkaloids, immuno suppressants, antibodies, avidin, biotin, clonazepam.
The hydrophobic drugs can be delivered for local delivery or as pre or post surgical therapies for the management of pain, osteomyelitis, osteosarcoma, joint infection, macular degeneration, diabetic eye, diabetes mellitus, psoriasis, ulcers, atherosclerosis, claudication, thrombosis viral infection, cancer or in the treatment of hernia.
In the context of the present invention the term "micelle(s)" refers only to the amphiphilic block copolymers assembled into a microphase separated, core/shell architecture in a selective organic solvent. A micelle (plural micelles, micella, or micellae) is an aggregate of amphiphilic molecules dispersed in a liquid. A typical micelle in aqueous solution forms an aggregate with the hydrophilic "head" regions in contact with surrounding solvent, sequestering the hydrophobic regions in the micelle centre. Micelles are approximately spherical in shape. Other phases, including shapes such as ellipsoids, cylinders, and rods are also possible. The shape and size of a micelle is a function of the molecular geometry of its molecules and solution conditions such as concentration, temperature, pH, and ionic strength.
The micelle composition according to the present invention may comprise a further hydrophobic core excipient such as a fatty acid, a vitamine or any hydrophobic polymer such as for example polycaprolactone. In this way the release properties can be further steered. Also the size of the micelles can be adjusted in this way.
The micelle composition of the present invention may optionally comprise a lyoprotectant. A lyoprotectant acts as a stabilizer for the loaded micelles during for example freeze drying. In this way the micelles do not coalesce so that the dried product does not readily disperse when an aqueous dispersant is added. The lyoprotectant can be a saccharide or polyol, for example, trehalose, sucrose or raffinose, or another hydrophilic polyol such as maltodextrin, fructose, glycerol, sorbitol, inositol and mannose. Lyoprotectants can also be materials other than sugars such as PEG.
Typically, the ratio of amphiphilic block copolymer to hydrophobic core excipient or lyoprotectant ranges from 1 :1 w/w to about 1 :50 w/w, preferably from 1 :1 w/w to 1 :10 w/w, advantageously to 1 :5 w/w.
The lyoprotectant can be added to the solvent along with the hydrophobic compound and the amphiphilic block copolymer or it can be added to water upon bringing into water, the solution of the hydrophobic compound and the amphiphilic block copolymer formed in the organic solvent.
The micelle composition according to the present invention may be a mixture of amphiphilic blockcopolymers. The micelle composition may further comprise an amphiphilic di block copolymer containing a hydrophobic block A and a hydrophilic block B wherein the hydrophobic block A comprises at least one hydrophobic polymer X and the hydrophilic block B comprises at least one hydrophilic polymer Y. The amount of diblock copolymer may vary up to 30 wt% of the total composition.
The micelles according to the present invention comprise an average particle size in the range of 10-800 nm, preferably 15-600 nm, more preferably 20-400 nm, most preferably in the range of 25-200 nm. The desired size is strongly dependent on the application and can be adjusted accordingly. The size of the micelles was determined by Dynamic Light Scattering (DLS) (Zetasizer Nano ZS, Malvern
Instruments Ltd., Malvern, UK) at 25°C at a scattering angle of 173°.
In general, micelles can be fabricated using a variety of techniques such as spray drying, freeze spray evaporation or emulsification (co-solvent evaporation). It is known to the person skilled in the art that the physical and chemical properties of micelles fabricated via emulsification, are greatly depended on the emulsification processing steps one applies for preparing the micelles. For example WO-A-03082303 discloses a process for the preparation of micelles which micelles comprise an amphiphilic block copolymers and a hydrophobic compound, and optionally a lyoprotectant or micelles' stabilizer. The process steps for producing the micelles include dissolving the hydrophobic compound and the amphiphilic block copolymer in a volatile organic solvent and then adding water to the miscible solution, with mixing, to promote the formation of micelles and the partitioning of the
hydrophobic compound into the micelle cores. The water is added slowly to induce micellization through the critical water content of the amphiphilic block copolymers (level of water required for assembly of the amphiphilic block copolymers). The water content is greater than the critical weight concentration (CWC). Subsequently, the organic solvent is removed by evaporation under reduced pressure or elevated temperature. After loading, the micelles based on the amphiphilic block copolymers can be freeze dried for later reconstitution.
One of the main disadvantages is of this process is the sensivity to the amount and the addition rate of water up to the critical weight concentration (CWC), both being critical for the micelle formation and stability of the micelles but also for the end average particle size and particle size distribution.
Therefore it is a further object of the present invention to provide a process for the preparation of the micelles not having the above disadvantages.
The present invention further relates to a process for preparing the micelle composition wherein the process comprises the steps of:
a) dissolving the hydrophobic compound and the amphiphilic block copolymer in an organic solvent to form a solution,
b) adding said organic solution into an aqueous medium,
c) optionally repeating aforementioned steps.
In a preferred embodiment, the hydrophobic compound is a therapeutic agent.
The micelle composition may also comprise more than one hydrophobic compound.
The concentration of the amphiphilic block copolymer in the organic solvent depends on the organic solvent used. For example in case that acetone is used as a solvent the concentration of the amphiphilic block copolymer at most 130 mg/mL (milligram per litre), preferably is at most 100 mg/L, more preferably is at most 65 mg/L.
As used in the context of the present invention, an organic solvent is a water miscible liquid used to produce a solution with at least one amphiphilic block copolymer and at least one hydrophobic compound. For use in the present methods, the solvent is one which desirably has a boiling temperature lower than that of water (less than 100 degrees centigrade at 1 atm). Preferably, the organic solvent forms an azeotrope with water, advantageously a negative azeotrope. Where the solvent and water form an azeotrope, the azeoptropic mixture can be dried by removing the azeotrope under conditions of decreased pressure and/or elevated temperature.
Examples include without limitation, acetone, methanol, ethanol, acetonitrile, tetrahydrofurane, propanol, isopropanol, ethyl acetate, etc.
In a preferred embodiment, the organic solvent is selected from the group consisting of acetone, tetrahydrofurane, methanol, ethanol, acetonitirile or mixtures thereof.
The aqueous medium is selected from the group consisting of water, saline solution or a buffer solution with a pH in the range of 1-14.
The process of the present invention offers enhanced control over the micelles' average particle size and distribution, the possibility to skip laborious and/or expensive process steps such as solvent evaporation, drying, sterilization, etc., Moreover the process is insensitive to the amount and/or the addition rate of water, it does not comprise a micelle's stabilizer such as a surfactant, it can be executed continuous on either small or large scale thus providing a robust, scalable and economically attractive method for the preparation of the micelle compositions.
The process of the present invention can also provide micelle compositions that can also exhibit one or more enhanced properties such as enhanced controlled release, enhanced self-life, being directly injectable and at the same time the concentration of the drug in the micelle composition can be tailored to meet dosage needs. Of course the process can be reversed to encapsulate hydrophilic compounds.
It is also possible to functionalize at least the surface of the micelles by providing at least the surface with a functional group, in particular with a signalling molecule, an enzyme or a receptor molecule, such as an antibody. The receptor molecule may for instance be a receptor molecule for a component of interest, which is to be purified or detected, e.g. as part of a diagnostic test, making use of the particles of the present invention. Suitable functionalisation methods may be based on a method known in the art.
In the context of the present invention the terms "method for the preparation" and "process" will be used interchangeably. Unless the context clearly indicates otherwise, as used herein plural forms of the terms herein are to be construed as including the singular form and vice versa.
For all upper and lower boundaries of any parameters given herein, the boundary value is included in each range for each parameter. All combinations of minimum and maximum values of the parameters described herein may be used to define the parameter ranges for various embodiments and preferences of the invention.
It will be understood that the total sum of any quantities expressed herein as percentages cannot (allowing for rounding errors) exceed 100 %. For example the sum of all components of which the composition of the invention (or part(s) thereof) comprises may, when expressed as a weight (or other) percentage of the composition (or the same part(s) thereof), total 100 % allowing for rounding errors. However where a list of components is non exhaustive the sum of the percentage for each of such components may be less than 100 % to allow a certain percentage for additional amount(s) of any additional compound(s) that may not be explicitly described herein.
The micelle composition of the present invention can be
administered, for example oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration and in pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, infraperitoneal,
subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time. The micelles of the invention can be
administered orally for example, with an inert diluent or with an assimilable edible carrier, it may be enclosed in hard or soft shell gelatin capsule, it may be compressed into tablets or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the micelles of the present invention may be incorporated within an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. The micelle composition of the invention may also be administered parenterally. Solutions of the micelle
composition according to the present invention can be prepared in water. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. A person skilled in the art would know how to prepare suitable formulations. The fields wherein the micelles according to the present invention can be used include dermatology, vascular, orthopedics, ophthalmic, spinal, intestinal, pulmonary, nasal, or auricular. Besides in a pharmaceutical application, the micelles according to the present invention may inter alia be used in an agricultural or food application. In particular, such micelles may comprise food additives, pesticides, insecticides or plant-nutrients.
The present invention further relates to articles comprising the micelle composition of the present invention. In another aspect, the invention provides for a device comprising the micelle composition of the present invention. In the context of the present invention, an article is an individual object or item or element of a class designed to serve a purpose or perform a special function and can stand alone.
In yet another preferred embodiment, the invention provides for a device comprising the article of the present invention. A device is a piece of equipment or a mechanism designed to serve a special purpose or perform a special function and can consist of more than one article (multi-article assembly).
Examples of devices include, but are not limited to catheters, stents, rods, implants.
In another aspect the invention provides for the use of the micelle composition of the invention, the article of the invention, the device of the invention in medical applications such as therapeutic cardiovascular applications, veterinary applications, food processing applications, flame retardant applications, coatings, adhesives and cosmetics, fabric/textiles, industrial and art applications.
In another preferred embodiment, the invention provides for a micelle composition of the present invention for use as a medicament.
In yet another preferred embodiment, the invention provides for the use of a micelle composition of the present invention for the manufacture of a medicament for cardiovascular therapeutic applications.
In another preferred embodiment the invention provides for a method for manufacturing a medicament intended for cardiovascular therapeutic applications characterized in that the micelle composition of the present invention is used.
The present invention will now be described in detail with reference to the following non limiting examples which are by way of illustration only. EXAMPLES
Materials and Methods.
-PLGA 20kDa was purchased from Ingelheim Boehringer.
-PCL 80kDa was purchased from Solvay
-PEG (3.0kDa and 6.0kDa), dexamethasone and Sn2Oct were purchased from Sigma Aldrich.
-Acetone was purchased from BASF.
-Rapamycin and paclitaxol were purchased from Oscar Tropitz.
-Saline was purchased from BBraun.
-Intensity-based Z-average as a particle size value measured by DLS
-Polydispersity (Pdl) is a measure of the width of the size distribution which is measured by the Malvern Zetasizer NanoZS.
-All other solvents are of analytical grade and purchased from Merck.
-Mn can be measured as followed. An example is given for PLGA.
Hydrolisation of PLGA with NaOH; PEG is unafected. The hydrolysis was performed in a closed bottle (or an autoclave(Roth, Karlsruhe, Germany) for 72 h at 140°C and 5 bar) with 2 mL PLGA or 20 mg solid sample and 200 μί 10 M NaOH solution for several days (3-7) at 90°C.
The concentration of glycolic acid and lactic acid was determined on an Agilent 1 100 LC-MS system, which consists of a binary pump, degasser, autosampler, column oven, diode-array detector and a time-of-flight-MS. The ESI-MS was run in negative mode, with the following conditions: m/z 50-3200, 215 V fragmentor, 0.94 cycl/sec, 350°C drying gas temperature, 12 L N2/min drying gas, 45 psig nebuliser pressure and 4 kV capillary voltage. UV detection was performed at 195 nm. The separation was performed with a 250x4.6 mm Prevail-C18 column (Alltech, USA) at room temperature and with a gradient of 50 mM sulfonic acid in ultra-pure water (mobile phase A) and acetonitrile (mobile phase B). The gradient was started at t=0 min with 99% (v/v) A, was stationary for 5 min and then changed linearly over 10 min to 90% (v/v) B (t=15 min). The flow rate was 0.5 mL/min and injection volume was 5 μί.
-The weight-average molecular weight (Mn) and concentration of PEG was determined by SEC using a highly polar hydroxylated methacrylate 8x300 mm Suprema 1000 A column (10 μηη particle size), with a separation range of 1 -100 kDa (PSS, Mainz, Germany). The mobile phase (0.1 M NH4Ac) was pumped at a flow rate of 1 .0 mL/min. The SEC analysis was performed using an Agilent 1 100 LC-DAD
system. Concentration and Mn can be analyzed using PEG calibration standards. Example 1 : Preparation of PLGA-PEG-PLGA triblock copolymers via ring opening polymerization.
PEG was weighed into a two-necked round bottle flask after drying for 24 hours in a vacuum oven at 90°C and subsequently placed in an oil bath at 150°C. A vacuum was employed for at least 60 minutes before continuing synthesis. The addition of lactide and glycolide (molar ratio of lactyl:glycolyl= 50:50) was carried out by removing the vacuum and at the same time flushing with nitrogen gas. Under stirring a homogenous melt was obtained after which stannous octoate (Sn2Oct), was added in the same way as the monomers. The reaction conditions were maintained for 20 hours where after the vacuum was replaced by nitrogen gas. The copolymers obtained in this wa are listed below.
Figure imgf000016_0001
C4H4O4
Mm=1 16.07 Mm=144.12
Figure imgf000016_0002
PEG-3000-diol
or
PEG-6000-diol
Batch 1 : Synthesis of PLGA(50/50)-PEG-PLGA(50/50) 7.5k-6k-7.5k
Actual Theory
- D,L-Lactide 3.9131 g 3.96g
- Glycolide 3.2471 g 3.19g
- PEG-6000-diol 2.8467g 2.86g
- Sn2Oct 2 drops 4.4mg
Batch 2: Synthesis of PLGA(50/50)-PEG-PLGA(50/50) 7.5k-6k-7.5k
Actual Theory
- D,L-Lactide 3.8461 g 3.96g - Glycolide 3.1664g 3.19g
- PEG-6000-diol 2.8597g 2.86g
- Sn2Oct 2 drops 4.4mg In batches 1 and 2, the amphiphilic block copolymer is a PLGA-PEG-
PLGA triblock copolymers wherein Mn A=7.5 kDa and Mn B=6 kDa.
The ratio R of the number average molecular weight (Mn) of block A (Mn A) divided to the number average molecular weight of block B (Mn B) is 2.5 and the amphiphilic block copolymer is characterised by parameter a being 5.24 and calculated as followed :
a = Mn A/ (MnA+ MnB) x K0/w A x VMtot in which
Mn A = 7.5 kDa 0/w monomeric units of A = Octanol/water partition coefficient of lactic acid/glycolic acid is1 .6.
Batch 3: Synthesis of PLGA(50/50)-PEG-PLGA(50/50) 3.75k-3k-3.75k
Actual Theory
D,L-Lactide 3.9098g 3.96g
Glycolide 3.3233g 3.19g
PEG-3000-diol 2.8573g 2.86g
Sn2Oct 2 drops 4.4mg
Batch 4: Synthesis of PLGA(50/50)-PEG-PLGA(50/50) 3.75k-3k-3.75k
Actual Theory
D,L-Lactide 3.9790g 3.96g
Glycolide 3.2620g 3.19g
PEG-3000-diol 2.8548g 2.86g
Sn2Oct 2 drops 4.4mg
In batches 3 and 4, Mn A=3.75 kDa and Mn B=3 kDa.
The ratio R= 2.5 and a =3.7 and calculated as follows:
a = Mn A / (MnA+ ΜΠΒ) X KO/W A X Mtot in which
Mn A = 3.75 kDa ΜΠΒ = 3 kDa K0/w = Octanol/water partition coefficient of lactic acid/glycolic acid is 1.6. Example 2: Preparation of PCL-PEG-PCL triblock copolymers via ring opening polymerization.
PEG was charged with ε-aprolactone in a 100ml round bottomed flask. The reaction mixture was heated to 100°C and stirred till a homogenous mixture was formed. A catalyst stock solution of tin(ll)octoate (58.1 mg, 0.143 mmol) was prepared in hexane (5 ml_). 1 ml. of the catalyst stock solution was added to the reaction mixture at 100°C. The reaction mixture was further heated to 150°C for an additional 18 hours (overnight) to allow the reaction to proceed. The following morning the reaction mixture was cooled to room temperature, an off white waxy solid material was obtained.
Batch 1 : Synthesis of PCL-PEG-PCL 1 .5k-3.0k-1.5k
Actual Theory
- ε-caprolactone 14.9980 g 0.131 mol
- PEG-3000-diol 15.0004 g 5.0 mmol
Sn2Oct-hexane solution (1 mL used in synthesis)
- Sn2Oct 58.1 mg 0.143 mmol
- Hexane 5mL In batch 1 the amphiphilic block copolymer is PCL-PEG-PCL triblock copolymer wherein Mn A=1 -5 kDa and Mn B=3 kDa.
The ratio R= 1 and a= 3.67 and calculated as follows :
a = Mn A (MnA+ ΜΠΒ) X KO/W A Mtot in which
Mn A = 1.5 kDa 0/w monomeric units ofA = Octanol/water partition coefficient of caprolacton is 3.
Batch 2: Synthesis of PCL-PEG-PCL 1 .7k-3.0k-1.7k
Actual Theory
- ε-caprolactone 15.9433 g 0.137 mol
- PEG-3000-diol 14.0628 g 4.7 mmol
Sn2Oct-hexane solution (1 mL used in synthesis)
- Sn2Oct 58.1 mg 0.143 mmol
- Hexane 5mL
In batch 2, Mn A=1 -7 kDa and Mn B=3 kDa. The ratio R=1.13 and a=4.03 and calculated as follows:
a = Mn A (MnA+ ΜΠΒ) X KO/W A Mtot in which
0/w monomeric units of A = Octanol/water partition coefficient of caprolacton is 3. Example 3: Purification of the synthesized triblock copolymers.
The triblock copolymers of examples 1 and 2 were dissolved in acetone at a weight percentage of 10-20% and filtered over an Acrodisc premium 25 mm Syringe filter, ΘχΡ/0.45μηη PVDF membrane, to remove particulate impurities and dust particles, which can interfere with the nanoprecipitation process. Hereafter the filtered solution was collected into a beaker of 500 ml. PTFE and evaporated to remove the solvent over night (10-12 hours) at maximum 40°C and minimum 300mbar.
The blockcopolymers were characterized by 1 H-NMR and GPC see
Table 1.
Figure imgf000019_0001
Example 4: Preparation of a drug loaded micelle composition based on PLGA-PEG- PLGA
855 mg (PLGA 3.75k)2-PEG 3k was dissolved in 14.25 ml Acetone selectipur. The solution was filtered over a 0.45 μηη filter to remove dust particles.
183.85 mg Rapamycin and 183.85 mg PLGA-PTE 20k were dissolved in the (PLGA 3.75k)2-PEG 3k / acetone solution. ([Rapa] = 12.9mg/ml).
The formulation was filtered over a 0.45 μηη filter to remove dust particles. 1 ml of the filtered formulation was pipetted into 25 ml of MilliQ water and measured by Dynamic light scattering (DLS).
Results and properties of the micelle composition are given in table 2. Example 5: Preparation of a drug loaded micelle composition based on PCL-PEG-PCL
1439.14 mg (PCL2k)2-PEG 3k was dissolved in Acetone selectipur (60 mg/ml). The polymer was filtered over a 0.45 μηη filter.
Rapamycin and PCL 80k was dissolved in the (PCL 2k)2-PEG 3k / Acetone solution. The formulation was filtered over a 0.45 μηη filter. 1 ml of the filtered formulation was pipetted into 25 ml of MilliQ water and measured by DLS.
Results and properties of the micelle composition are given in table 2.
Table 2
Figure imgf000020_0001
Example 6: Preparation of micelle compositions based on PLGA-PEG-PLGA
A. Micelles made from different concentrations triblockcopolymer.
a. 32.1 mg PEG (6k) - (PLGA (7.5k))2 was dissolved in 1 ml acetone, 0.400ml of the solution was added to 10 ml Milli Q.
b. 64.5 mg PEG (6k) - (PLGA (7.5k))2 was dissolved in 1 ml acetone, 0.400ml of the solution was added to 10 ml Milli Q.
Results and properties of the micelle composition are given in table 3.
B. Micelles at different pH values
a. 64.5 mg PEG (6k) - (PLGA (7.5k))2 was dissolved in 1 ml acetone, 0.400ml of the solution was added to 10 ml pH buffer (CertiPUR buffer: citric acid / sodium hydroxide / hydrogen chloride), pH=4. b. 64.5 mg PEG (6k) - (PLGA (7.5k))2 was dissolved in 1 ml acetone, 0.400ml of the solution was added to 10 ml pH buffer (CertiPUR buffer: boric acid/ potassium chloride / sodium hydroxide), pH=9.
Results and properties of the micelle composition are given in table 3.
C. Micelles in different salt solution
a. 64.5 mg PEG (6k) - (PLGA (7.5k))2 was dissolved in 1 ml acetone, 0.400ml of the solution was added to 10 ml 0.9% NaCI.
Results and properties of the micelle composition are given in table 3.
D. Micelles in salt and pH controlled solution
a. 64.5 mg PEG (6k) - (PLGA (7.5k))2 was dissolved in 1 ml acetone, 0.400ml of the solution was added to 10 ml PBS, pH=7.4 (=sodium chloride / potassium chloride / sodium phosphate)
Results and properties of the micelle composition are given in table 3.
Table 3: Properties of the micelle compositions
Figure imgf000021_0001
Example 7: Size stability of micelle compositions in time.
164.1 mg (PLGA 7.5k)2-PEG 6k was dissolved in 2.400ml Acetone selectipur. The solution was filtered over a 0.45 μηη filter to remove dust particles.
0.8 mg Rapamycin was dissolved in 0.800ml acetone solution. The formulation was filtered over a 0.45 μηη filter to remove dust particles.
0.3000 ml of the (PLGA 7.5k)2-PEG 6k-acetone solution was mixed with 0.100ml of the rapamycin-acetone solution, resulting in 0.400 ml of (PLGA 7.5k)2- PEG 6k/Rapamycin-acetone solution The 0.400ml of the of (PLGA 7.5k)2-PEG 6k/Rapamycin-acetone solution was pipetted into 10 ml of MilliQ water and measured by Dynamic light scattering (DLS).
Time (days) z-average (i
Day 1 : 45.28
Day 2: 43.81
Day 15: 45.27
Example 8: Size stability of micelle compositions in time.
164.1 mg (PLGA 7.5k)2-PEG 6k was dissolved in 2.400ml Acetone selectipur. The solution was filtered over a 0.45 μηη filter to remove dust particles.
0.3000 ml of the (PLGA 7.5k)2-PEG 6k-acetone solution was mixed with 0.100ml of aacetone solution, resulting in 0.400 ml of (PLGA 7.5k)2-PEG 6k- acetone solution
The 0.400ml of the of (PLGA 7.5k)2-PEG 6k-acetone solution was pipetted into 10 ml of MilliQ water and measured by Dynamic light scattering (DLS).
Time (days) z-average (nm) Pdl
Day 1 : 48.69 0.188
Day 15: 49.08 0.100

Claims

A micelle composition comprising comprising an amphiphilic block copolymer containing a hydrophobic block A and a hydrophilic block B, whereby the ratio R of the number average molecular weight (Mn) of block A (Mn A) divided to the number average molecular weight of block B (Mn B) is higher than 0.95 and whereby the amphiphilic block copolymer is characterised by a parameter a whereby ;
3 < a < 5.5;
a = MnA/ (MnA+MnB) x K0/w x VMtot in which
Mn A = number average molecular weight (Mn) of block A
MnB = number average molecular weight (Mn) of block B
K0/W A = Octanol/water partition coefficient of the monomeric units of hydrophobic block A
Figure imgf000024_0001
whereby the hydrophobic block A comprises at least one hydrophobic polymer X and the hydrophilic block B comprises at least one hydrophilic polymer Y and wherein the amphiphilic block copolymer is a triblock copolymer.
Micelle composition according to claim 1 further comprising a hydrophobic compound.
Micelle composition according to any one of the claims 1-2 wherein the average particle size of the micelles is in the range of 10-200 nm.
Micelle composition according to anyone of the claims 2-3 wherein the hydrophobic compound is selected from the group of therapeutic agents, cardiovascular drugs, vitamins, flavour agents, food ingredients, pigments, catalysts, photo-or UV-stabilizers, fungicides, insecticides, flame retardants or anticancer drugs.
Micelle composition according to claim 4 wherein the hydrophobic compound is a cardiovascular drug.
Micelle composition according to anyone of the claims 1-5 wherein the hydrophobic polymer X is selected from the group consisting of poly(lactic acid), poly(D,L-lactide-co-glycolide), poly(e-caprolactone),
poly(hydroxybutyrate), poly(tetramethylene carbonate) or poly(ester amides). Micelle composition according to anyone of the claims 1-6, wherein the hydrophilic polymer Y is selected from the group consisting of poly(ethylene oxide), poly(ester amide), polyvinylpyrrolidone or polyvinylacetate.
Micelle composition according to anyone of the claims 1-7, wherein the amphiphilic block copolymer is a triblock copolymer comprising X-Y-X.
Micelle composition according to claim 8 wherein the triblock copolymer comprises polylactic acid, a hydrophobic polyesteramide or polycaprolactone as hydrophobic polymer X and polyethyleneglycol or a hydrophilic
polyesteramide as hydrophilic polymer Y.
Micelle composition according to any one of the claims 1-9 wherein the micelle composition may further comprise a further hydrophobic core excipient.
Micelle composition according to any one of the claims 1-10 wherein the micelle composition further comprises an amphiphilic di block copolymer containing a hydrophobic block A and a hydrophilic block B wherein the hydrophobic block A comprises at least one hydrophobic polymeric unit X and the hydrophilic block B comprises at least one hydrophilic polymeric unit Y. Micelle composition according to claim 1 1 wherein the amount of diblock copolymer may vary up to 30 wt% of the total composition.
A process for the preparation of the micelle composition according to any one of the claims 1-10 wherein the process comprises the steps of:
a. dissolving the hydrophobic compound and the amphiphilic block
copolymer in an organic solvent to form a solution,
b. adding said organic solution into an aqueous medium,
c. optionally repeating aforementioned steps.
A process according to claim 13 wherein the process further comprises the following steps:
d. evaporating the organic solvent thus forming an aqueous solution, e. optionally repeating aforementioned step with the steps described in claim 13.
f. filtering said aqueous solution to obtain the micelle composition, g. optionally drying said micelles.
A process according to any one of claims 13 wherein the aqueous medium is selected from the group consisting of water, saline solution or a buffer solution with a pH in the range of 1 -14.
16. A process according to any one of claims 13-14 wherein the organic solvent is selected from the group consisting of acetone, tetrahydrofuran, methanol, ethanol, acetonitirile or mixtures thereof.
17. An article comprising the micelle composition according to any one of the claims 1-12.
18. A device comprising the micelle composition according to any one of the
claims 1-12.
19. A device comprising the article of claim 18.
20. Use of the micelle composition according to any one of the claims 1 -12, the article according to claim 17 or the device according to any one of the claims 18-19 in medical applications such as therapeutic cardiovascular applications, veterinary applications, cancer applications, food processing applications, flame retardancy applications, coatings, adhesives and cosmetics, fabric/textiles, industrial and art applications.
21. Use of the micelle composition according to claim 20 wherein the micelle composition is used in an amount that allows the micelle composition to exhibit its controlled release properties.
22. A micelle composition according to any one of the claims 1-12 for use as a medicament.
23. Use of a micelle composition as defined in any one of the claims 1 -12 for the manufacture of a medicament for cardiovascular applications.
24. Use of the micelle composition as defined in the claims 1 -12 for the
manufacture of a medicament for cancer treatment.
PCT/EP2011/053817 2010-03-12 2011-03-14 Micelle compositions and process for the preparation thereof WO2011110694A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US13/634,445 US20130102687A1 (en) 2010-03-12 2011-03-14 Micelle compositions and process for the preparation thereof
CA2791559A CA2791559A1 (en) 2010-03-12 2011-03-14 Micelle compositions and process for the preparation thereof
JP2012556544A JP5842270B2 (en) 2010-03-12 2011-03-14 Micelle composition and method for its preparation
CN201180013635.XA CN102791255B (en) 2010-03-12 2011-03-14 Micelle composition and preparation method thereof
EP11707688A EP2544661A2 (en) 2010-03-12 2011-03-14 Micelle compositions and process for the preparation thereof
US15/159,736 US20160271062A1 (en) 2010-03-12 2016-05-19 Micelle compositions and process for the preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10156372A EP2382966A1 (en) 2010-03-12 2010-03-12 Micelle compositions and process for the preparation thereof
EP10156372.4 2010-03-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/634,445 A-371-Of-International US20130102687A1 (en) 2010-03-12 2011-03-14 Micelle compositions and process for the preparation thereof
US15/159,736 Continuation US20160271062A1 (en) 2010-03-12 2016-05-19 Micelle compositions and process for the preparation thereof

Publications (2)

Publication Number Publication Date
WO2011110694A2 true WO2011110694A2 (en) 2011-09-15
WO2011110694A3 WO2011110694A3 (en) 2012-01-19

Family

ID=42320981

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2011/052249 WO2011110407A2 (en) 2010-03-12 2011-02-15 Micelle compositions and process for the preparation thereof
PCT/EP2011/053817 WO2011110694A2 (en) 2010-03-12 2011-03-14 Micelle compositions and process for the preparation thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/052249 WO2011110407A2 (en) 2010-03-12 2011-02-15 Micelle compositions and process for the preparation thereof

Country Status (6)

Country Link
US (3) US20110223206A1 (en)
EP (2) EP2382966A1 (en)
JP (1) JP5842270B2 (en)
CN (1) CN102791255B (en)
CA (1) CA2791559A1 (en)
WO (2) WO2011110407A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017192544A1 (en) * 2016-05-02 2017-11-09 Massachusetts Institute Of Technology AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi
EP3150195B1 (en) * 2014-05-23 2020-03-11 Shimadzu Corporation Skin external preparation and skin irritation-reducing method

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271884A1 (en) * 2011-10-25 2014-09-18 The Trustees Of Princeton University High-loading nanoparticle-based formulation for water-insoluble steroids
PL405241A1 (en) 2013-09-04 2015-03-16 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Polymer micelle, method of producing and application
US9557337B2 (en) 2013-10-02 2017-01-31 Becton, Dickinson And Company Polymersome encapsulation of hydrophobic fluorescent polymers
US9284414B2 (en) 2013-11-26 2016-03-15 Globalfoundries Inc. Flame retardant polymers containing renewable content
US9346922B2 (en) 2013-11-26 2016-05-24 International Business Machines Corporation Flame retardant block copolymers from renewable feeds
KR102365648B1 (en) 2014-04-14 2022-02-21 아키나, 인크. Novel hydrogel tissue expanders
WO2016004369A1 (en) 2014-07-02 2016-01-07 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
CN105062021B (en) * 2015-08-18 2017-03-01 九江学院 A kind of non-temperature sensitive degradable polymer latex and preparation method thereof
MX2018012291A (en) * 2016-04-08 2019-08-05 Battelle Memorial Institute Encapsulation compositions.
US11034786B2 (en) 2016-06-16 2021-06-15 Lg Chem, Ltd. Amphiphilic triblock polymer
WO2017217813A1 (en) * 2016-06-16 2017-12-21 주식회사 엘지화학 Amphiphilic polymer
CN109312035B (en) 2016-06-16 2021-07-30 株式会社Lg化学 Amphiphilic polymers
CN106726770A (en) * 2016-12-28 2017-05-31 广州环亚化妆品科技有限公司 A kind of makeup removing micelle composition and preparation method thereof and the application in makeup remover
WO2018175268A1 (en) * 2017-03-19 2018-09-27 Biohealthways, Inc. Biodegrading implantable ocular sustained release drug delivery system
US10278572B1 (en) 2017-10-19 2019-05-07 Obp Medical Corporation Speculum
US10376468B2 (en) * 2017-12-05 2019-08-13 International Business Machines Corporation Block copolymers and self-assembling nanoparticles formed therefrom
EP3723731A4 (en) * 2017-12-12 2021-10-20 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
CN109734901B (en) * 2018-12-21 2021-05-04 东华大学 Polypeptide-based polyester ammonia-type nano particle and preparation and application thereof
CN109734900B (en) * 2018-12-21 2021-05-04 东华大学 Enzyme-degradable polypeptide-based polyester ammonia and preparation method and application thereof
CN113350268B (en) * 2021-06-17 2023-09-05 复旦大学附属眼耳鼻喉科医院 Drug sustained-release gel for subconjunctival implantation and preparation method thereof
CN113750918B (en) * 2021-08-17 2022-06-17 常州大学 Method for preparing patch-shaped anisotropic spherical micelle based on micromolecule non-covalent post-modification
CN114656651B (en) * 2022-03-17 2024-05-07 西安交通大学 Multi-arm star polymer assembled micelle and preparation method thereof
CN115364046B (en) * 2022-08-16 2024-04-30 上海交通大学医学院附属第九人民医院 Thermosensitive sol for treating vasospasm and preparation method and application thereof
CN117126308B (en) * 2023-08-28 2024-02-23 天津大学 Photonic crystal pigment based on host-guest interaction and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010849A1 (en) 1995-09-21 1997-03-27 Sam Yang Co., Ltd. Copolymeric micelle drug composition and method for the preparation thereof
US5683723A (en) 1991-06-28 1997-11-04 Rhone-Poulenc Rorer S.A. Nanoparticles based on a polyoxyethelene and polyactic acid block copolymer
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
WO2003082303A1 (en) 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
WO2005118672A1 (en) 2004-06-02 2005-12-15 The Governors Of The University Of Alberta Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010030891A (en) * 1997-10-03 2001-04-16 마크로메드 인코퍼레이션 BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
US6541033B1 (en) * 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US20020192286A1 (en) * 2001-03-27 2002-12-19 Macromed, Incorporated Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
EP1393718A1 (en) * 2002-08-29 2004-03-03 OctoPlus Sciences B.V. Colloidal drug carrier system
TWI248947B (en) * 2003-07-21 2006-02-11 Ind Tech Res Inst Biodegradable copolymer, and polymeric micelle composition containing the copolymer
EP1765285A2 (en) * 2004-06-16 2007-03-28 University of Massachusetts Poly (lactid acid) copolymer hydrogels and related methods of drug delivery
WO2006110862A2 (en) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
US20070135504A1 (en) * 2005-12-11 2007-06-14 Marshall Trevor G Method of Treating and/or Preventing Inflammatory Diseases, including many Autoimmune and Neurological diseases, using drugs to modulate the VDR, and/or PPAR, and/or GCR and/or CB1 nuclear and GPCR receptors; in conjunction with antibiotics which target prokaryotic protein translation
TWI314465B (en) * 2005-12-30 2009-09-11 Ind Tech Res Inst Thermosensitive nanostructure for hyperthermia treatment
US20100203114A1 (en) * 2007-07-09 2010-08-12 Warf - Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683723A (en) 1991-06-28 1997-11-04 Rhone-Poulenc Rorer S.A. Nanoparticles based on a polyoxyethelene and polyactic acid block copolymer
WO1997010849A1 (en) 1995-09-21 1997-03-27 Sam Yang Co., Ltd. Copolymeric micelle drug composition and method for the preparation thereof
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
WO2003082303A1 (en) 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
WO2005118672A1 (en) 2004-06-02 2005-12-15 The Governors Of The University Of Alberta Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAVIS, S.S ET AL., INT. J. PHARM., 1998, pages 179,2
JONES, M.C ET AL., EUR. J. PHARM. BIOPHARM., vol. 48, 1999, pages 101
See also references of EP2544661A2

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150195B1 (en) * 2014-05-23 2020-03-11 Shimadzu Corporation Skin external preparation and skin irritation-reducing method
WO2017192544A1 (en) * 2016-05-02 2017-11-09 Massachusetts Institute Of Technology AMPHIPHILIC NANOPARTICLES FOR CODELIVERY OF WATER-INSOLUBLE SMALL MOLECULES AND RNAi
WO2017192573A1 (en) * 2016-05-02 2017-11-09 Massachusetts Institute Of Technology Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer
WO2017192512A3 (en) * 2016-05-02 2017-12-14 Massachusetts Institute Of Technology Amphiphilic nanoparticles for delivery of crispr based therapy
US10751423B2 (en) 2016-05-02 2020-08-25 Massachusetts Institute Of Technology Nanoparticle conjugates of highly potent toxins and intraperitoneal administration of nanoparticles for treating or imaging cancer
US11730826B2 (en) 2016-05-02 2023-08-22 Massachusetts Institute Of Technology Amphiphilic nanoparticles for delivery of CRISPR based therapy

Also Published As

Publication number Publication date
US20160271062A1 (en) 2016-09-22
JP5842270B2 (en) 2016-01-13
WO2011110694A3 (en) 2012-01-19
EP2382966A1 (en) 2011-11-02
EP2544661A2 (en) 2013-01-16
CN102791255B (en) 2016-02-17
CN102791255A (en) 2012-11-21
US20130102687A1 (en) 2013-04-25
WO2011110407A3 (en) 2012-01-12
US20110223206A1 (en) 2011-09-15
JP2013522178A (en) 2013-06-13
WO2011110407A2 (en) 2011-09-15
CA2791559A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
US20130102687A1 (en) Micelle compositions and process for the preparation thereof
AU2001262756B2 (en) Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001258872B2 (en) Method for the preparation of polymeric micelle via phase separation of block copolymer
CA2709993A1 (en) Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
AU2001258872A1 (en) Method for the preparation of polymeric micelle via phase separation of block copolymer
US11179466B2 (en) Amphiphilic block copolymer composition having enhanced micelle stability, and pharmaceutical composition comprising same
EP3177669B1 (en) Amphiphilic blockcopolymers comprising reduction sensitive biodegradable polyesteramides
WO2004022036A1 (en) Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release
CA2634830A1 (en) Degradable polymeric microsphere composition
EP3004202B1 (en) Copolymer and nanoparticles obtained therefrom for drug delivery
CN1296097C (en) Polymer micelle medicine-carrying system
Ouyang et al. Fabrication of hydrophilic paclitaxel-loaded PLA-PEG-PLA microparticles via SEDS process
Danafar Synthesis and Characterization of mpeg-PCL Copolymers as a Polymersomes for Delivery of Enalapril as a Model Hydrophilic Drug: Drug delivery of enalapril by polymersomes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180013635.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11707688

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2011707688

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011707688

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 6793/DELNP/2012

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2012556544

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2791559

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13634445

Country of ref document: US